Nucleic acids — in the form of oligonucleotides, mRNA, or mRNA variants— can be a transformative modality. We know that oligo synthesis has been around for over 20 years, but oligonucleotides have recently begun to hit the market in large numbers.
Curious about how manufacturers went from producing zero mRNA vaccines per year to producing millions? Katarina Stenklo pulls back the curtain on rapid scale-up of nucleic acid therapeutics.
